2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6209 Real-world clinical course of warm autoimmune hemolytic anemia: A global retrospective chart review

Erik Clarke, Doug Schlichting, PhD2, Cathye Shu3, Gurinderpal Doad4, Joan Cid, MD, PhD5, Ronald Go, MD6, Irina Murakhovskaya, MD7, Corentin Orvain, MD PhD8, Iige Viigimaa9, Wayne Thomas10, Michal Witkowski11, Maryanne Okubanjo12, Sara K S Bengtsson13, Rebecca Zaha14
1 Johnson & Johnson, Spring House, Pennsylvania, United States
2 Johnson & Johnson, Spring House, Pennsylvania, United States
3 Johnson & Johnson, Spring House, Pennsylvania, United States
4 Johnson & Johnson, Spring House, Pennsylvania, United States
5 Department of Hemotherapy and Hemostasis, ICAMS, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
6 Mayo Clinic, Rochester, Minnesota, United States
7 Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States
8 Maladies du Sang, CHU d’Angers, Angers, France
9 North Estonia Medical Centre Foundation, Tallinn, Estonia
10 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
11 Copernicus Memorial Hospital, Lodz, Poland, Foundation for Leukemia Patients, Lodz, Poland
12 BC Platforms, Zurich, Switzerland
13 BC Platforms, Zurich, Switzerland
14 Johnson & Johnson, Spring House, Pennsylvania, United States

Background: Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening disease characterized by IgG autoantibody-mediated premature destruction of red blood cells. Real-world data on treatment patterns and clinical outcomes remain limited due to disease rarity, complex disease trajectories, incomplete coding, and a lack of lab data integration.

Aim: This global, multicenter, retrospective chart review used pharmacoepidemiologic analyses to characterize patient demographics, hematologic responses, and treatment practices in a real-world population with wAIHA from initial study sites in the United States and Europe.

Methods: Records from consenting adult patients with primary or secondary wAIHA and no history of cold AIHA, cold agglutinin disease, mixed AIHA, or paroxysmal cold hemoglobinuria who were not enrolled in any interventional study were identified. The study period ranged from January 1, 2017–March 31, 2023. A patient’s index date was defined as the earliest date in this period that fulfilled the criteria of 1) a date ≥3 months after initial diagnosis, 2) after the start of their 1st treatment for wAIHA, and 3) with a lab result for any of the following labs: direct antiglobulin test (DAT), indirect bilirubin, lactate dehydrogenase (LDH), or reticulocyte count. Data from patient records were extracted into a secure data environment and standardized to a common schema.

Outcomes assessed included durable hemoglobin (Hgb) response (Hgb ≥10 g/dL with a ≥2 g/dL increase from index over ≥3 lab tests spanning ≥28 days starting by the 16th week after the index date without any intravenous [IV] corticosteroids [CS], IVIg, or blood transfusion), sustained normalization of hemolytic markers (simultaneous attainment of normal LDH, haptoglobin, and indirect bilirubin on 3 consecutive timepoints each ≥2 weeks apart), treatment patterns, and safety.

Results: A total of 162 patients from 2 US and 6 European sites were included in the current analysis. Median age at index was 66 years (IQR, 53-77) and 91 participants (56%) were female; 88 (54%) were enrolled from the United States and 74 (46%) from Europe. For the 88 US patients, median age was 65 years (IQR, 48.0-76.5) and 50 participants (57%) were female. Overall, the median time since diagnosis at index was 3.8 months (IQR, 3.2–30) and median observation time was 2.5 years (IQR, 1.1-4.3). For the 66 (40.7%) patients who had available Hgb data at diagnosis, mean Hgb was 7.4 g/dL (IQR, 6.4-8.5). 77% of patients had primary wAIHA. Prior to the index date, 58% of patients received CS without other immunosuppressants, 44% received rituximab in conjunction with CS, and 50% had blood transfusion(s).

At index, mean Hgb was 12.1 g/dL (IQR, 10.5–13.4; mean change from diagnosis: 4.2). Of 123 patients with available data, 14 (11.4%; 95% CI, 6.4–18.4) achieved a durable Hgb response any time during the observation period, while 4 of 30 with available data (13.3%; 95% CI, 3.8–30.7) achieved sustained normalization of hemolytic markers.

Of 162 total patients, 73 (45%) were on a course of CS at the index date and 110 patients (68%) received CS at any point during the observational period. Median duration of oral CS therapy was 209 days (IQR, 102-481), at a median average daily dose (prednisone equivalent) of 25 mg/day (IQR, 8.5-45). Fewer patients were treated with rituximab during the same period (49/162 [30.2%]). The rate of any infection among patients was 9.2 per 100 patient-years (95% CI, 6.6-12.5).

Conclusions: In one of the largest global real-world wAIHA datasets to date with 162 patients, this retrospective analysis provides contemporary insights into the clinical course and management of wAIHA. From diagnosis to index, a 4.2 g/dL increase in mean Hgb was observed (from 7.4 g/dL at diagnosis); however, achievement of durable Hgb response during the study period (ie, after index date) was limited at 11.4% despite >6 months of corticosteroid treatment, highlighting the need for long-term treatment strategies in this population.
Erik Clarke: Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment